Results 11 to 20 of about 585,966 (213)

Second-generation inhibitors of Bruton tyrosine kinase

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +2 more sources

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny [PDF]

British Journal of Pharmacology
Bruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B-cell proliferative disorders.
Camilli, Massimiliano, Menna, Pierantonio   +1 more
core   +4 more sources

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Clinical Hematology International, 2022
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh, Hassan Abushukair, Aref Qarqash, Sebawe Syaj, Samer Al Hadidi   +4 more
doaj   +2 more sources

Editorial: Targeting Bruton Tyrosine Kinase

Frontiers in Cell and Developmental Biology, 2022
Cornelia Brunner, Annika C. Betzler, Jennifer R. Brown, Amy H. Andreotti, Emanuela Grassilli   +4 more
doaj   +5 more sources

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +2 more sources

Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton\u27s Tyrosine Kinase Inhibitors [PDF]

, 2023
Bruton\u27s tyrosine kinase (BTK) is a promising molecular target for several human B-cell-related autoimmune disorders, inflammation, and haematological malignancies.
Marián , Hajdúch, Narendran , Annadurai, Chandra Prakash , Koraboina, Soňa , Gurská, Petr, Džubák, Venkatanarayana Chowdary , Maddipati, Rambabu , Gundla, Viswanath, Das   +7 more
core   +2 more sources

Bruton\u27s tyrosine kinase supports gut mucosal immunity and commensal microbiome recognition in autoimmune arthritis [PDF]

, 2022
Bruton\u27s tyrosine kinase
Thurman, Christina E, Barron, Bridgette B, Reboldi, Andrea, Kendall, Peggy L, Bonami, Rachel H, Verma, Sonam, Nyhoff, Lindsay E, Westlake, Camille S   +7 more
core   +1 more source

Targeting Bruton’s Tyrosine Kinase in CLL [PDF]

Frontiers in Immunology, 2021
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. Covalent BTK inhibitors (BTKis) led to an unprecedented improvement in outcome in CLL, in particular for high-risk subgroups with TP53 aberration and unmutated immunoglobulin ...
Inhye E. Ahn, Jennifer R. Brown
openaire   +3 more sources

A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context

, 2021
The use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of a number of hematological conditions is rapidly increasing. Ibrutinib is the most clinically advanced and common BTK inhibitor currently utilized.
Johnston, J, Mortimore, R, Robertson, I, Van Rooij, N   +3 more
core   +1 more source

BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]

, 2009
Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is ...
van, Loo PF, Hendriks, RW
core   +1 more source